Intravesical sequential gemcitabine/docetaxel for non-muscle invasive bladder cancer: tips and tricks for better efficacy and tolerability
J Chemother. 2024 Mar 4:1-4. doi: 10.1080/1120009X.2024.2325765. Online ahead of print.NO ABSTRACTPMID:38439550 | DOI:10.1080/1120009X.2024.2325765 (Source: Journal of Chemotherapy)
Source: Journal of Chemotherapy - March 5, 2024 Category: Cancer & Oncology Authors: Mohamad Abou Chakra Mohamad Moussa Michael A O'Donnell Source Type: research

Antimicrobial dosing recommendations during continuous renal replacement therapy: different databases, different doses
In this study, we aimed to compare current databases that are frequently used to adjust CRRT dosages of antimicrobial drugs with the gold standard. The dosage recommendations from various databases for antimicrobial drugs eliminated by CRRT were investigated. The book 'Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys' was chosen as the gold standard. There were variations in the databases. Micromedex, UpToDate, and Sanford had similar rates to the gold standard of 45%, 35%, and 30%, respectively. The Micromedex database shows the most similar results to the gold standard source. In addition...
Source: Journal of Chemotherapy - February 27, 2024 Category: Cancer & Oncology Authors: Aysel Pehlivanli Tu ğba Yanik Yalçin Fatma İrem Yeşiler Helin Şahintürk Özlem Kurt Azap P ınar Zeyneloğlu Bilgen Ba şgut Source Type: research

Amikacin treatment in urinary tract infection patients: evaluating the risk of acute kidney injury - a retrospective cohort study
J Chemother. 2024 Feb 19:1-5. doi: 10.1080/1120009X.2024.2319454. Online ahead of print.ABSTRACTThe rise in ESBL-producing and carbapenem-resistant Gram-negative bacterial infections is alarming. Aminoglycosides remain attractive for treating urinary tract infections (UTIs). However, aminoglycosides-associated acute kidney injury (AKI) raises concerns, especially in patients with underlying renal impairment. We conducted a retrospective cohort study to evaluate the risk of AKI in patients with UTI empirically treated with amikacin. Among 395 patients (median age 41.9 years [IQR 28.3-67.1], 342 [86.6%] female), 162 (41.0%) ...
Source: Journal of Chemotherapy - February 19, 2024 Category: Cancer & Oncology Authors: Avner Dagan Danny Epstein Ami Neuberger Jonathan Isenberg Source Type: research